trending Market Intelligence /marketintelligence/en/news-insights/trending/jK_ereZ9P75EzRBqgS9c3g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA grants fast track designation to Radius Health's breast cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA grants fast track designation to Radius Health's breast cancer drug

The U.S. Food and Drug Administration granted fast-track designation to Radius Health Inc.'s breast cancer drug estrogen.

The company said the drug is being evaluated in two ongoing phase 1 studies and will be evaluated in a phase 2 study in early 2018.